Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:BRNS NASDAQ:JSPR NASDAQ:NBRV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.59-4.8%$5.13$1.42▼$75.00$12.58M0.66500,306 shs204,321 shsBRNSBarinthus Biotherapeutics$1.33+4.7%$1.27$0.64▼$2.92$51.71M-0.7525,194 shs29,854 shsJSPRJasper Therapeutics$2.69-1.1%$3.41$2.27▼$26.05$44.21M2.77204,458 shs133,767 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.70%+3.09%-72.17%-84.68%-93.75%BRNSBarinthus Biotherapeutics+9.86%+7.63%-1.55%+28.28%-5.22%JSPRJasper Therapeutics-1.45%-6.21%-8.42%-52.28%-85.82%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.59-4.8%$5.13$1.42▼$75.00$12.58M0.66500,306 shs204,321 shsBRNSBarinthus Biotherapeutics$1.33+4.7%$1.27$0.64▼$2.92$51.71M-0.7525,194 shs29,854 shsJSPRJasper Therapeutics$2.69-1.1%$3.41$2.27▼$26.05$44.21M2.77204,458 shs133,767 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.70%+3.09%-72.17%-84.68%-93.75%BRNSBarinthus Biotherapeutics+9.86%+7.63%-1.55%+28.28%-5.22%JSPRJasper Therapeutics-1.45%-6.21%-8.42%-52.28%-85.82%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$9.93 per shareN/ABRNSBarinthus Biotherapeutics$14.97M3.62N/AN/A$3.23 per share0.41JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$17.54M-$79.10N/A∞N/AN/A-89.02%-75.32%9/29/2025 (Estimated)BRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)JSPRJasper Therapeutics-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ALatest BIVI, BRNS, JSPR, and NBRV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025JSPRJasper Therapeutics-$1.20-$1.74-$0.54-$1.74N/AN/A8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.109.10BRNSBarinthus BiotherapeuticsN/A7.897.89JSPRJasper TherapeuticsN/A2.102.10NBRVNabriva Therapeutics0.120.850.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%BRNSBarinthus Biotherapeutics25.20%JSPRJasper Therapeutics79.85%NBRVNabriva Therapeutics0.27%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%BRNSBarinthus Biotherapeutics10.70%JSPRJasper Therapeutics4.60%NBRVNabriva Therapeutics1.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie107.53 million7.35 millionNo DataBRNSBarinthus Biotherapeutics10740.72 million36.36 millionN/AJSPRJasper Therapeutics2016.25 million15.51 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableBIVI, BRNS, JSPR, and NBRV HeadlinesRecent News About These CompaniesNabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comMeitheal gains rights to ContempoJuly 20, 2024 | thepharmaletter.comTMeitheal gains rights to CONTEPO from Nabriva in North AmericaJuly 19, 2024 | pharmaceutical-technology.comPNabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comMNabriva Therapeutics files patent for a dosing regimen for fosfomycin treatmentDecember 22, 2023 | pharmaceutical-technology.comPArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comNabriva Therapeutics Provides Corporate UpdateJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | marketwatch.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | markets.businessinsider.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | bizjournals.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | seekingalpha.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infectionsNovember 10, 2022 | bioworld.comBMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, BRNS, JSPR, and NBRV Company DescriptionsBioVie NASDAQ:BIVI$1.59 -0.08 (-4.79%) Closing price 04:00 PM EasternExtended Trading$1.61 +0.02 (+1.19%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Barinthus Biotherapeutics NASDAQ:BRNS$1.33 +0.06 (+4.72%) Closing price 03:59 PM EasternExtended Trading$1.18 -0.15 (-10.90%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Jasper Therapeutics NASDAQ:JSPR$2.69 -0.03 (-1.10%) Closing price 04:00 PM EasternExtended Trading$2.67 -0.02 (-0.74%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
